ENG/中
老虎證券
市场
行情
24/7新闻
产品
Cash Boost账户
期权
A股通
港股
固定票息票据
美股
ETF
基金超市
美国国债
新加坡股
期货
Tiger BOSS Debit Card
老虎钱袋子
功能
经纪人
定投
CPF/SRS 投资
专栏
美股碎股
TigerAI
费用
综合账户
股票与ETF
期权、窝轮与牛熊证
期货
债券
基金超市
Cash Boost
股票与ETF
融资利率
活动
帮助
账户操作
如何开户
开户文件
账户类型
资金与转仓
入金
DDA快捷入金
出金
转入股票
转出股票
货币兑换
产品与交易
可交易产品
订单类型
交易规则
申报
融资融券
保证金与杠杆
风险管理
做空风险
基金超市
基金开户与交易
Cash Boost账户
Cash Boost 账户FAQ
如何开通 Cash Boost 账户
如何用Cash Boost 账户交易
如何绑定CDP证券账户
Tiger Boss Debit Card
常见问题
费用说明
如何充值
如何使用我的Debit card
账单报表
账单报表
股息(分红)
机构
Tiger Fund Management
机构服务
财富及资产管理人
自营交易机构
介绍经纪商
三方服务商
老虎API平台
登入
立即註冊
Toggle
港股
詳情
本頁面由Tiger Trade Technology Pte. Ltd.提供服務
醫美概念股
902.195
-20.647
-2.24%
手動刷新
漲家數:
5
跌家數:
6
平家數:
2
市盈率:
- -
高:
922.651
開:
922.651
低:
893.993
收:
922.842
成交量:
1.34億
成交額:
9.37億
市值:
1,484.98億
流通市值:
1,113.66億
資料載入中...
總覽
新聞
康哲藥業(00867.HK)將於9月8日派發中期股息每股0.189港元
智通财经
·
08/17
康哲藥業(00867)公布中期業績 公司擁有人應占溢利按年增長4.77%至9.86億元
智通财经网
·
08/17
復星醫藥子公司攜生物類似藥出海 牽手全球仿製藥龍頭,鎖定四成銷售分成
每日经济新闻
·
08/17
復星醫藥(02196.HK)控股子公司復宏漢霖與Sandoz AG簽訂合作框架協議並達成許可
智通财经
·
08/17
復星醫藥擬與山德士合作,共同推進多達10款生物藥的商業化、開發與生產
美股速递
·
08/17
{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/stock/BK1593/news?page=4"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1593","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1593\",,,,,undefined,":{"symbol":"BK1593","market":"HK","secType":"PLATE","nameCN":"醫美概念股","latestPrice":902.19464,"timestamp":1788163726135,"preClose":922.8416,"halted":0,"volume":133996901,"delay":0,"changeRate":-0.022373,"floatShares":0,"shares":0,"eps":0,"marketStatus":"已收盤","change":-20.646973,"latestTime":"08-31 16:00:00","open":922.6513,"high":922.6513,"low":893.9928,"amount":937121311,"amplitude":0.031055,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1788226200000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1788139800000,1788148800000],[1788152400000,1788163200000]],"pbRate":1.180847,"peRate":10.919282,"turnoverRate":0.006236,"increases":4,"decrements":7,"flats":2,"marketCap":148497744360,"floatMarketCap":111366366760},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1593\",,,,,undefined,":{"symbol":"BK1593","high":922.6513,"amplitude":0.031055,"preClose":922.8416,"low":893.9928,"pbRate":"1.180847","latestPrice":902.19464,"volume":133996901,"delay":0,"open":922.6513,"prevYearClose":1094.978,"prevWeekClose":922.842,"prevMonthClose":920.614,"prevQuarterClose":846.145,"fiveDayClose":948.522,"twentyDayClose":935.405,"sixtyDayClose":858.687,"secType":"PLATE","market":"HK","turnoverRate":0.006236,"peRate":10.919282,"marketCap":148497744360,"floatMarketCap":111366366760,"timestamp":1788163726135,"nameCN":"醫美概念股"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1593\",,,,undefined,":{"bkCode":"BK1593","up":5,"down":6,"flat":2},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1593\",pageSize:20,pageCount:4,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2660382734","title":"康哲藥業(00867.HK)將於9月8日派發中期股息每股0.189港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2660382734","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660382734?lang=zh_tw&edition=fundamental","pubTime":"2026-08-17 21:30","pubTimestamp":1786973419,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["SG9999015952.SGD","SG9999015978.USD","SG9999015945.SGD","IE00BVYPNP33.GBP","IE00BGHQDM52.EUR","00867","LU2488822045.USD","IE00BMCWC346.EUR","BK1191","IE00BYV24P56.USD","IE00BVYPNQ40.USD","SG9999015986.USD","BK1593","SG9999004220.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660497438","title":"康哲藥業(00867)公布中期業績 公司擁有人應占溢利按年增長4.77%至9.86億元","url":"https://stock-news.laohu8.com/highlight/detail?id=2660497438","media":"智通财经网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660497438?lang=zh_tw&edition=fundamental","pubTime":"2026-08-17 21:28","pubTimestamp":1786973287,"startTime":"0","endTime":"0","summary":"康哲药业(00867)公布2026年中期业绩,营业额同比增长 12.5%至约45亿元,毛利同比增长 11.4%至约32.21亿元,期间溢利同比增长 \n4.3%至9.715亿元,公司拥有人应占溢利同比增长4.77%至9.86亿元,每股基本盈利0.4075 元,中期股息每股0.1634元。","market":"us","thumbnail":"https://img.zhitongcaijing.com/gonggaonew/ganggugongg15.jpg?x-oss-process=image/format,jpg/quality,Q_100/resize,h_300","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/gonggaonew/ganggugongg15.jpg?x-oss-process=image/format,jpg/quality,Q_100/resize,h_300"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1481036.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"康哲药业(00867)公布中期业绩 公司拥有人应占溢利同比增长4.77%至9.86亿元","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["IE00BYV24P56.USD","IE00BVYPNQ40.USD","LU2488822045.USD","BK1593","SG9999015986.USD","IE00BGHQDM52.EUR","IE00BVYPNP33.GBP","SG9999015978.USD","SG9999004220.SGD","IE00BMCWC346.EUR","SG9999015952.SGD","BK1191","00867","SG9999015945.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660866704","title":"復星醫藥子公司攜生物類似藥出海 牽手全球仿製藥龍頭,鎖定四成銷售分成","url":"https://stock-news.laohu8.com/highlight/detail?id=2660866704","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660866704?lang=zh_tw&edition=fundamental","pubTime":"2026-08-17 17:26","pubTimestamp":1786958770,"startTime":"0","endTime":"0","summary":"8月17日,复星医药(SH600196,股价24.01元,市值588.9亿元)公告披露,其控股子公司复宏汉霖与全球生物类似药龙头SandozAG于8月16日签订《合作框架协议》。双方约定,可就复宏汉霖至多10款单克隆抗体(mAb)和/或抗体偶联药物(ADC)生物类似药,开展海外区域的注册、商业化、开发、生产等许可合作,并已就首批3款产品达成具体商业条款。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608173843260444.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608173843260444.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1992135472.HKD","LU2473716301.USD","LU2322448791.USD","BK0187","IE00B5TLWC47.USD","600196","BK1593","LU2272731600.USD","BK0188","BK1191","BK0060","BK0012","BK0183","LU1992135399.USD","02196","IBB","LU2272731782.SGD","BK0096","LU2322448957.HKD","BK0196","PPH","BK4585","BK1515","BK0028","LU2272731865.HKD","XPH","BK0239","BK4588","BK0175"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660059911","title":"復星醫藥(02196.HK)控股子公司復宏漢霖與Sandoz AG簽訂合作框架協議並達成許可","url":"https://stock-news.laohu8.com/highlight/detail?id=2660059911","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660059911?lang=zh_tw&edition=fundamental","pubTime":"2026-08-17 08:34","pubTimestamp":1786926890,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["HK0000306701.USD","HK0000320223.HKD","HK0000306685.HKD","BK1191","HK0000320264.USD","BK1161","HK0000165453.HKD","02196","BK1515","BK1593","02696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129073878","title":"復星醫藥擬與山德士合作,共同推進多達10款生物藥的商業化、開發與生產","url":"https://stock-news.laohu8.com/highlight/detail?id=1129073878","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1129073878?lang=zh_tw&edition=fundamental","pubTime":"2026-08-17 08:03","pubTimestamp":1786924988,"startTime":"0","endTime":"0","summary":"复星医药宣布,计划与山德士携手,围绕多达10款生物制品展开合作。合作范围涵盖商业化、开发以及生产等关键环节。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0096","02196","BK0239","BK0012","BK1593","BK0060","BK0188","BK0196","BK1515","BK0175","BK1191","600196","BK0183","BK0187","BK0028"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":4,"totalSize":65,"code":"91000000","status":"200"}]}}